PMID- 23509459
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130320
LR  - 20211021
IS  - 1687-8337 (Print)
IS  - 1687-8345 (Electronic)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Cellular signaling pathway alterations and potential targeted therapies for 
      medullary thyroid carcinoma.
PG  - 803171
LID - 10.1155/2013/803171 [doi]
LID - 803171
AB  - Parafollicular C-cell-derived medullary thyroid cancer (MTC) comprises 3% to 4% 
      of all thyroid cancers. While cytotoxic treatments have been shown to have 
      limited efficacy, targeted molecular therapies that inhibit rearranged during 
      transfection (RET) and other tyrosine kinase receptors that are mainly involved 
      in angiogenesis have shown great promise in the treatment of metastatic or 
      locally advanced MTC. Multi-tyrosine kinase inhibitors such as vandetanib, which 
      is already approved for the treatment of progressive MTC, and cabozantinib have 
      shown distinct advantages with regard to rates of disease response and control. 
      However, these types of tyrosine kinase inhibitor compounds are able to 
      concurrently block several types of targets, which limits the understanding of 
      RET as a specific target. Moreover, important resistances to tyrosine kinase 
      inhibitors can occur, which limit the long-term efficacy of these treatments. 
      Deregulated cellular signaling pathways and genetic alterations in MTC, 
      particularly the activation of the RAS/mammalian target of rapamycin (mTOR) 
      cascades and RET crosstalk signaling, are now emerging as novel and potentially 
      promising therapeutic treatments for aggressive MTC.
FAU - Giunti, Serena
AU  - Giunti S
AD  - Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, 50019 
      Firenze, Italy.
FAU - Antonelli, Alessandro
AU  - Antonelli A
FAU - Amorosi, Andrea
AU  - Amorosi A
FAU - Santarpia, Libero
AU  - Santarpia L
LA  - eng
PT  - Journal Article
DEP - 20130221
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3594951
EDAT- 2013/03/20 06:00
MHDA- 2013/03/20 06:01
PMCR- 2013/02/21
CRDT- 2013/03/20 06:00
PHST- 2012/11/12 00:00 [received]
PHST- 2013/01/08 00:00 [revised]
PHST- 2013/01/10 00:00 [accepted]
PHST- 2013/03/20 06:00 [entrez]
PHST- 2013/03/20 06:00 [pubmed]
PHST- 2013/03/20 06:01 [medline]
PHST- 2013/02/21 00:00 [pmc-release]
AID - 10.1155/2013/803171 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:803171. doi: 10.1155/2013/803171. Epub 2013 Feb 21.